

## Expanded Access Policy

BioInvent International is a clinical-stage biotech company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy. We have several drug candidates in our ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer as well as solid tumors.

At BioInvent, we are focused on enrolling and conducting the clinical trials necessary to gain regulatory approvals to make our medicines available to patients as quickly as possible. As such, we believe participation in our clinical trial is the most appropriate way to access our new treatments at this early stage of development.

BioInvent understands the interest of patients and healthcare providers in accessing new therapies outside of clinical trials and prior to being available on the market for potentially life-threatening diseases. However, we do not offer any of our developmental medicines through expanded access programs, except for patients who could benefit for continued treatment upon completion of one of our clinical trials. We recognize the need for Expanded Access programs and will re-evaluate the status of our policy based on emerging data from ongoing and future clinical trials.

We encourage those who are interested in learning more about our clinical development programs, including eligibility criteria and locations to visit [clinicaltrials.gov](https://clinicaltrials.gov).